Search

A case report describes a 24-year-old transgender man who developed respiratory symptoms, specifically dyspnea, while being treated for bipolar II disorder with cariprazine, lurasidone, and lumateperone. The patient had a history of psychiatric disorders and asthma, which was well-controlled. The respiratory symptoms improved when lurasidone and cariprazine were discontinued, but worsened again when the patient switched to lumateperone. A decrease in the dose of lumateperone partially improved the asthma symptoms, but worsened the patient's mood. Ultimately, the patient achieved stabilization with lumateperone and valproic acid, but continued to experience depressive and mild-moderate respiratory symptoms. [Extracted from the article]

In a retrospective study, two transgender men aged 49-54 years who were undergoing gender-affirming mastectomy and receiving testosterone as hormone therapy developed invasive ductal breast carcinoma. Both patients presented with gender dysphoria and had been on testosterone therapy for a year. After undergoing gender-affirming mastectomy, they were diagnosed with breast cancer related to testosterone therapy. One patient received letrozole therapy, but both patients chose to continue testosterone treatment. [Extracted from the article]

A 77-year-old transgender man who was undergoing treatment for grade-2 invasive lobular carcinoma experienced weight gain, itching of the vagina, and discharge from the vagina while taking tamoxifen. The patient had previously undergone various surgeries and was receiving testosterone replacement therapy. After developing serious adverse effects, tamoxifen was discontinued and letrozole was started. The patient's invasive lobular carcinoma remained stable with the new treatment. [Extracted from the article]

A 56-year-old transgender man developed poorly-differentiated endometrial carcinoma while undergoing gender-affirming therapy with testosterone. The patient had been on testosterone and finasteride therapy since 2015, but in 2022, they developed vaginal discharge and sought medical attention. Imaging tests revealed a thickened endometrium and a PET-CT scan showed hypermetabolic activity in the endometrial lining. The patient underwent a hysterectomy and the tumor was found to be necrotic with no glandular pattern. The diagnosis of poorly-differentiated endometrial carcinoma was made based on symptoms and investigative findings. [Extracted from the article]

A retrospective study described two cases of drug-induced liver injury (DILI) in patients undergoing gender transition and bodybuilding supplementation. The first case involved a 21-year-old transgender man who developed DILI after receiving testosterone-undecanoate for female-to-male transition. The second case involved a 44-year-old man who developed DILI after taking ligandrol, enobosarm, acetyl-tyrosine/alpha-ketoglutarate/arginine/ascorbic-acid/beta-alanine/caffeine/cobalamin/creatine/folic-acid/mucuna-pruriens/niacin/pyridoxine/theacrine, and whey-protein. Both patients experienced complications, including kidney injury and liver failure, but eventually showed improvement. These cases highlight the potential risks of certain medications and supplements on liver health. [Extracted from the article]

A 41-year-old transgender individual who was undergoing hormone replacement therapy with testosterone developed stage IIIA invasive metastatic endometrial adenocarcinoma. The patient had been receiving testosterone injections and anastrozole as hormone replacement therapy. The cancer was discovered after the patient experienced vaginal bleeding and underwent a biopsy. The occurrence of the cancer was attributed to the testosterone treatment. The patient underwent surgery, radiation, and chemotherapy, and chose to delay re-initiation of hormone replacement therapy due to concerns about the potential impact on cancer recurrence. [Extracted from the article]

A 33-year-old transgender man developed endometrioid endometrial adenocarcinoma while undergoing testosterone treatment for medical gender transition. The patient had been receiving exogenous testosterone therapy but developed stage IV endometrioid endometrial adenocarcinoma, which was believed to be a result of the testosterone therapy. The patient underwent surgical resection for symptom control and received palliative chemotherapy. After a discussion of the risks and benefits, testosterone therapy was resumed postoperatively. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 31-year-old transgender man (female to male) patient developed myocardial infarction while receiving hormonal therapy with testosterone-propionate/testosterone-phenylpropionate/testosterone-isocaproate/testosterone-decanoate for gender transformation. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 27-year-old transgender man (female at birth and transitioned to male) developed prolactinoma recurrence during treatment with testosterone-cypionate as female to male transgender hormonal therapy [route, duration of treatment to reaction onset and outcome not stated]. [Extracted from the article]

Two case reports describe men who developed Brugada syndrome and drug intolerance while undergoing treatment with testosterone. In the first case, a 26-year-old man developed iatrogenic hypopituitarism and received testosterone for three years before experiencing a cardiac arrest. He was treated with quinidine but developed drug intolerance, leading to radiofrequency ablation and implantation of a cardioverter defibrillator. The second case involved a 21-year-old transgender man who developed syncope while driving after one year of testosterone treatment. He also received quinidine and underwent radiofrequency ablation and implantation of a cardioverter defibrillator. The unmasking of Brugada syndrome was attributed to testosterone treatment in both cases. [Extracted from the article]

A case report published in Reactions Weekly describes a female-to-male transgender patient who experienced weight gain while taking mirtazapine for anxiety and depression. The patient also developed polycythemia during gender-affirming hormone therapy with testosterone undecanoate. The patient had a history of low mood, anxiety, and depression, and had undergone various surgeries as part of their transition. The weight gain was attributed to mirtazapine, and the polycythemia was considered a side effect of testosterone undecanoate. The patient's treatment was adjusted, and their hemoglobin and testosterone levels returned to normal. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: Drug overdose * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 35-year-old man developed intracranial hypertension (IH) during treatment with testosterone cipionate in overdose for mild hypogonadism. On examination, grade 2 papilledema, normal cell count, elevated CSF protein and CSF opening pressure were noted. [Extracted from the article]

Erythrocytosis occurs in more than ten percent of trans men using testosterone, according to study results reported in the I Journal of Clinical Endocrinology and Metabolism i , and "a person who is stable on testosterone therapy for years can still develop first-time erythrocytosis". The risk of HCT >0/5 L/L was highest for long-acting testosterone undecanoate injections, with short-acting ester injections and oral administration having a similar risk to gel formulations. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A case series described two female to male transgender patients, of whom, a 30-year-old patient developed acne and hidradenitis suppurativa (HS) during masculinising hormone therapy (MHT) with testosterone-cipionate for gender dysphoria, while a 40-year-old patient developed worsening of HS during MHT with testosterone-cipionate for gender dysphoria [ I durations of treatments to reactions onsets not stated i ]. Approximately after 1.5 years of therapy initiation, the patient's testosterone-cipionate dose was increased to 140 mg/week. Prior to testosterone-cipionate initiation, the patient only had involvement of the patient's axillae and posterior neck. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A multi-centre prospective study [Study ID: NCT01072825] of 106 patients described two female to male transgender patients and five male to female transgender patients [ I ages not stated i ], who developed major depression, galactorrhoea, hypertension, skin irritation or muscle and joint aches during cross-sex hormone therapy (CHT) with cyproterone, estradiol, unspecified estrogen receptor agonists or testosterone-undecanoate [ I durations of treatments to reactions onsets not stated; i I not all routes, dosages and outcomes stated i ]. Meanwhile, two transmen developed muscle and joint aches (n=2), which were attributed to testosterone-undecanoate, while the five transwomen developed major depression (n=1), galactorrhoea (n=1), hypertension (n=1) or skin irritation (n=2), which were attributed to cyproterone, estradiol patch or unspecified estrogen receptor agonists. Two transwoman, who had developed skin irritation due to estradiol patches, were switched to other therapies after 3 months (1 patient) and 9 months (1 patient) of treatment. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 50-year-old female-to-male (FtM) transsexual developed ductal carcinoma in situ during treatment with testosterone for masculinisation. Before mastectomy, the patient refrained from the national population screening program for breast cancer and had not undergone mammography. After 1 year of undergoing mastectomy, the patient was healthy with no signs of malignancy. [Extracted from the article]

This article discusses research being done on an adverse effect of isotretinoin. It references a study by A. L. Isenstein and colleagues in the July 2006 issue of the "British Journal of Dermatology." During treatment with isotretrinoin for acne, a female-to-male transsexual suffered vaginal bleeding. The administration of the drug is described. The results of the physical and laboratory examination conducted on the patient are presented.